Project Updates and Milestones news (page 38)

19 March 2026

FDA approves Novo Nordisk’s Wegovy HD (7.2 mg) after ~21% weight loss in STEP UP trial

Higher‑dose semaglutide injection approved for adults with obesity after tolerating 2.4 mg; 31% reached ≥25% weight loss. Common AEs: GI symptoms and dysesthesia/altered skin sensation. Available April.
19 March 2026

QatarEnergy: Missile strikes cut LNG export capacity 17%, $20bn annual loss

Missile strikes at Ras Laffan damaged LNG Trains 4 & 6; repairs may take 3–5 years with force majeure on contracts. Pearl GTL offline ≥1 year; condensate, LPG, naphtha and helium production affected.
19 March 2026

Aptar’s Unidose Nasal Powder System Used in ENA Respiratory Phase II INNA‑051 Study

Powder nasal device used in a Phase II trial of a once-weekly spray to assess safety, tolerability and reduction of symptomatic infections; device offers single-dose precision and moisture protection.
19 March 2026

OMV and ADNOC delay BGI listing, exchange offer and capital increase to 2027

Timing aligned to a 2027 capital increase; 2026 dividend cut will lower parent payout by ~€0.6–0.7/sh (payout USD250m vs USD500m). Further support measures possible.
19 March 2026

Novo Nordisk: FDA approves Wegovy HD (semaglutide 7.2 mg) — 20.7% mean weight loss

STEP UP: ~31% achieved ≥25% loss; STEP UP T2D mean loss 14.1%. FDA awarded National Priority Voucher. US launch expected April 2026. Safety/tolerability comparable to prior semaglutide doses.
19 March 2026

ADNOC and OMV progress formation of Borouge Group International AG

New asset-usage deal for Borouge 4 secures USD 400m cumulative net profit over three years, ~10% EPS accretion, adds 1.5Mt cracker/1.4Mt PE and lifts combined capacity to 13.6Mt.

The right choices in the European chemical industry

Save time with chemXplore Alpha

Learn more

← Previous Next →